Name: Lyophilized Injectable Drugs Market Size, Competitive Landscape and Market Forecast - 2029
Brand: DataM Intelligence
SKU: MD1274
Price: 4350 USD
Availability: InStock

Lyophilized Injectable Drugs Market Size Share Growth Opportunities and Forecast 2022

Lyophilized Injectable Drugs Market Size, Competitive Landscape and Market Forecast - 2029

<h2>Global Lyophilized Injectable Drugs Market is segmented&nbsp;By Type of Delivery (Multi-step Devices, Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-step Devices),&nbsp;By Indication (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, Oncology, Others),&nbsp;By Type of Packaging (Point-of-Care Reconstitution, Specialty Packaging, Single-use Vials),&nbsp;By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global &quot;Lyophilized Injectable Drugs Market&quot;&nbsp;is expected to grow at a high&nbsp;<a href="https://www.datamintelligence.com/download-sample/lyophilized-injectable-drugs-market">CAGR</a>&nbsp;during the forecasting period (2022-2029).
</blockquote>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/lyophilization-services-for-biopharmaceuticals-market">Lyophilization Services for Biopharmaceuticals Market</a>

<a href="https://www.datamintelligence.com/research-report/lyophilization-freeze-drying-equipment-market">Lyophilization/Freeze Drying Equipment Market</a>

<a href="https://www.datamintelligence.com/research-report/connected-drug-delivery-devices-market">Connected Drug Delivery Devices Market</a>

<h3>&nbsp;</h3>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

1. Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Type of Delivery

3.2. Market Snippet by Indication

3.3. Market Snippet by Type of Packaging

3.4. Market Snippet by End User

3.5. Market Snippet by Region

4. Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Rise in chronic health conditions

4.1.1.2. Rising geriatric population

4.1.2. Restraints

4.1.2.1. Availability of Lyophilized Injectable Drugs alternatives

4.1.3. Opportunity

4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter&#39;s Five Forces Analysis

5.2. Regulatory Analysis

6. Epidemiology Analysis

7. Pipeline Analysis

8. By Type of Delivery

8.1.1.&nbsp;Introduction

8.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

8.1.3. Market Attractiveness Index, By Type of Delivery

8.2. Multi-step Devices

8.2.1. Introduction

8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

8.3. Prefilled Diluent Syringes

8.4. Proprietary Reconstitution Devices

8.5. Single-step Devices

9. By Indication

9.1.1.&nbsp;Introduction

9.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

9.1.3. Market Attractiveness Index, By Indication

9.2. Autoimmune Diseases

9.2.1. Introduction

9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

9.3.&nbsp;&nbsp;&nbsp;&nbsp;Infectious Diseases

9.4. Metabolic Conditions

9.5. Oncology

9.6.&nbsp;&nbsp;&nbsp;Others

10. By Type of Packaging

10.1.1.&nbsp;Introduction

10.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

10.1.3. Market Attractiveness Index, By Type of Packaging

10.2. Point-of-Care Reconstitution

10.2.1. Introduction

10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

10.3.&nbsp;Specialty Packaging

10.4. Single-use Vials

11. By End User

11.1.1.&nbsp;Introduction

11.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11.1.3. Market Attractiveness Index, By End User

11.2. Hospitals

11.2.1. Introduction

11.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

11.3. Specialty Clinics

11.4. Ambulatory Surgical Centers

11.5. Others

12. By Region

12.1. Introduction

12.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

12.1.2. Market Attractiveness Index, By Region

12.2. North America

12.2.1. Introduction

12.2.2. Key Region-Specific Dynamics

12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By

Indication

12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By

Country

12.2.7.1. The U.S.

12.2.7.2. Canada

12.2.7.3. Mexico

12.3. Europe

12.3.1. Introduction

12.3.2. Key Region-Specific Dynamics

12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.3.7.1. Germany

12.3.7.2. The U.K.

12.3.7.3. France

12.3.7.4. Italy

12.3.7.5. Spain

12.3.7.6. Rest of Europe

12.4. South America

12.4.1. Introduction

12.4.2. Key Region-Specific Dynamics

12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.4.7.1. Brazil

12.4.7.2. Argentina

12.4.7.3. Rest of South America

12.5. Asia Pacific

12.5.1. Introduction

12.5.2. Key Region-Specific Dynamics

12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12.5.7.1. China

12.5.7.2. India

12.5.7.3. Japan

12.5.7.4. Australia

12.5.7.5. Rest of Asia Pacific

12.6. Middle East &amp; Africa

12.6.1. Introduction

12.6.2. Key Region-Specific Dynamics

12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Packaging

12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Delivery

12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

&nbsp;

13. Competitive Landscape

13.1.&nbsp;&nbsp;Competitive Scenario

13.2.&nbsp;Competitor&nbsp;Lyophilized Injectable Drugs Strategy Analysis

13.3. Comparative Product Portfolio Analysis

13.4. Market Positioning/Share Analysis

13.5. Mergers and Acquisitions Analysis

&nbsp;

14. - Company Profiles

14.1. Becton, Dickinson and Company

14.1.1. Company Overview

14.1.2. Product Portfolio and Description

14.1.3. Key Highlights

14.1.4. Financial Overview

14.2. Burrard Pharmaceuticals

14.3.&nbsp;Cirondrugs

14.4.&nbsp;CordenPharma International

14.5.&nbsp;Emergent BioSolutions Inc.

14.6.&nbsp;Jubilant HollisterStier LLC

14.7.&nbsp;Mylan N.V.

14.8.&nbsp;Recipharm AB

14.9.&nbsp;S. G. Biopharm Pvt. Ltd.

14.10.&nbsp;Schott AG

&nbsp;

16. DataM Intelligence

16.1. Appendix

16.2. About Us and Services

16.3. Contact Us

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables and Figures</h2>

<h3>List of Tables</h3>

TABLE 01.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, 2021, 2025 &amp; 2029 , BY TYPE OF DELIVERY, ($MILLION)

TABLE 02.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE 2021, 2025 &amp; 2029 , BY TYPE OF PACKAGING, ($MILLION)

TABLE 03.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE 2021, 2025 &amp; 2029 , BY INDICATION, ($MILLION)

TABLE 03.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE 2021, 2025 &amp; 2029 , BY END USER, ($MILLION)

TABLE 04.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE 2021, 2025 &amp; 2029 , BY REGION, ($MILLION)

TABLE 05.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY TYPE OF DELIVERY ($MILLION)

TABLE 06.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 07.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY TYPE OF PACKAGING ($MILLION)

TABLE 08.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY APPICATION, 2021&ndash;2029 ($MILLION)

TABLE 09.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY INDICATION ($MILLION)

TABLE 10.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 10.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY END USER ($MILLION)

TABLE 11.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 12.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY REGION ($MILLION)

TABLE 13.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY REGION, 2021&ndash;2029 ($MILLION)

TABLE 14.&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 15.&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

TABLE 16.&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 16.&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 17.&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY COUNTRY, 2021&ndash;2029 ($MILLION)

TABLE 18.&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 19.&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

TABLE 20.&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 21.&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 22.&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY COUNTRY, 2021&ndash;2029 ($MILLION)

TABLE 23.&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 24.&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

TABLE 25.&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 26.&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 27.&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY COUNTRY, 2021&ndash;2029 ($MILLION)

TABLE 28.&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 29.&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

TABLE 30.&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 31.&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 32.&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY COUNTRY, 2021&ndash;2029 ($MILLION)

TABLE 33.&nbsp;&nbsp;&nbsp;MIDDLE EAST &amp; AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

TABLE 34.&nbsp;&nbsp;&nbsp;MIDDLE EAST &amp; AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

TABLE 35.&nbsp;&nbsp;&nbsp;MIDDLE EAST &amp; AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INDICATION, 2021&ndash;2029 ($MILLION)

TABLE 36.&nbsp;&nbsp;&nbsp;MIDDLE EAST &amp; AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY END USER, 2021&ndash;2029 ($MILLION)

TABLE 37.&nbsp;&nbsp;&nbsp;BECTON, DICKINSON AND COMPANY: OVERVIEW

TABLE 38.&nbsp;&nbsp;&nbsp;BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 39.&nbsp;&nbsp;&nbsp;BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS

TABLE 40.&nbsp;&nbsp;&nbsp;BURRARD PHARMACEUTICALS: OVERVIEW

TABLE 41.&nbsp;&nbsp;&nbsp;BURRARD PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 42.&nbsp;&nbsp;&nbsp;BURRARD PHARMACEUTICALS: KEY DEVELOPMENTS

TABLE 43.&nbsp;&nbsp;&nbsp;CIRONDRUGS: OVERVIEW

TABLE 44.&nbsp;&nbsp;&nbsp;CIRONDRUGS: PRODUCT PORTFOLIO

TABLE 45.&nbsp;&nbsp;&nbsp;CIRONDRUGS: KEY DEVELOPMENTS

TABLE 46.&nbsp;&nbsp;&nbsp;CORDENPHARMA INTERNATIONAL: OVERVIEW

TABLE 47.&nbsp;&nbsp;&nbsp;CORDENPHARMA INTERNATIONAL: PRODUCT PORTFOLIO

TABLE 48.&nbsp;&nbsp;&nbsp;CORDENPHARMA INTERNATIONAL: KEY DEVELOPMENTS

TABLE 49.&nbsp;&nbsp;&nbsp;B. BRAUN MELSUNGEN AG: OVERVIEW

TABLE 50.&nbsp;&nbsp;&nbsp;B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO

TABLE 51.&nbsp;&nbsp;&nbsp;B. BRAUN MELSUNGEN AG: KEY DEVELOPMENTS

TABLE 52.&nbsp;&nbsp;&nbsp;JUBILANT HOLLISTERSTIER LLC: OVERVIEW

TABLE 53.&nbsp;&nbsp;&nbsp;JUBILANT HOLLISTERSTIER LLC: PRODUCT PORTFOLIO

TABLE 54.&nbsp;&nbsp;&nbsp;JUBILANT HOLLISTERSTIER LLC: KEY DEVELOPMENTS

TABLE 55.&nbsp;&nbsp;&nbsp;MYLAN N.V.: OVERVIEW

TABLE 56.&nbsp;&nbsp;&nbsp;MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 57.&nbsp;&nbsp;&nbsp;MYLAN N.V.: KG: KEY DEVELOPMENTS

TABLE 58.&nbsp;&nbsp;&nbsp;RECIPHARM AB.: OVERVIEW

TABLE 59.&nbsp;&nbsp;&nbsp;RECIPHARM AB.: PRODUCT PORTFOLIO

TABLE 60.&nbsp;&nbsp;&nbsp;RECIPHARM AB.: KEY DEVELOPMENTS

TABLE 61.&nbsp;&nbsp;&nbsp;S. G. BIOPHARM PVT. LTD: OVERVIEW

TABLE 62.&nbsp;&nbsp;&nbsp;S. G. BIOPHARM PVT. LTD: PRODUCT PORTFOLIO

TABLE 63.&nbsp;&nbsp;&nbsp;S. G. BIOPHARM PVT. LTD: KEY DEVELOPMENTS

TABLE 64.&nbsp;&nbsp;&nbsp;SCHOTT AG.: OVERVIEW

TABLE 65.&nbsp;&nbsp;&nbsp;SCHOTT AG.: PRODUCT PORTFOLIO

TABLE 66.&nbsp;&nbsp;&nbsp;SCHOTT AG.: KEY DEVELOPMENTS

&nbsp;

<h3>List of Figures</h3>

FIGURE 01.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE, 2021 &amp; 2029 (%), BY TYPE OF DELIVERY

FIGURE 02.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE, 2021 &amp; 2029 (%), BY TYPE OF PACKAGING

FIGURE 03.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE, 2021 &amp; 2029 (%), BY INDICATION

FIGURE 04.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE, 2021 &amp; 2029 (%), BY END USER

FIGURE 05.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET SHARE, 2021 &amp; 2029 (%), BY REGION

FIGURE 06.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, 2021 - 2029 AND YEAR ON YEAR GROWTH

FIGURE 07.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET YEAR ON YEAR GROWTH 2021 TO 2029 (%), BY TYPE OF DELIVERY

FIGURE 08&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, BY MULTI-STEP DEVICES, 2021&ndash;2029 ($MILLION)

FIGURE 09&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, BY PREFILLED DILUENT SYRINGES, 2021&ndash;2029 ($MILLION)

FIGURE 10&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, BY PROPRIETARY RECONSTITUTION DEVICES, 2021&ndash;2029 ($MILLION)

FIGURE 11&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE, BY SINGLE-STEP DEVICES, 2021&ndash;2029 ($MILLION)

FIGURE 12.&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET YEAR ON YEAR GROWTH 2021 TO 2029 (%), BY TYPE OF PACKAGING

FIGURE 13&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY POINT-OF-CARE RECONSTITUTION, 2021&ndash;2029 ($MILLION)

FIGURE 14&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY SPECIALTY PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 15&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY SINGLE-USE VIALS, 2021&ndash;2029 ($MILLION)

FIGURE 16&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET YEAR ON YEAR GROWTH 2021 TO 2029 (%), BY INDICATION

FIGURE 17&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY AUTOIMMUNE DISEASES, 2021&ndash;2029 ($MILLION)

FIGURE 18&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY INFECTIOUS DISEASES, 2021&ndash;2029 ($MILLION)

FIGURE 19&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY METABOLIC CONDITIONS, 2021&ndash;2029 ($MILLION)

FIGURE 20&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY OTHERS, 2021&ndash;2029 ($MILLION)

FIGURE 21&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET YEAR ON YEAR GROWTH 2021 TO 2029 (%), BY END USER

FIGURE 22&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY HOSPITALS, 2021&ndash;2029 ($MILLION)

FIGURE 23&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY SPECIALTY CLINCS, 2021&ndash;2029 ($MILLION)

FIGURE 24&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY AMBULATORY SURGICAL CENTERS, 2021&ndash;2029 ($MILLION)

FIGURE 25&nbsp;&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , BY OTHERS, 2021&ndash;2029 ($MILLION)

FIGURE 26&nbsp;&nbsp;&nbsp;GLOBAL LYOPHILIZED INJECTABLE DRUGS MARKET YEAR ON YEAR GROWTH 2021 TO 2029 (%), BY REGION

FIGURE 27&nbsp;&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , 2021&ndash;2029 ($MILLION)

FIGURE 28&nbsp;&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY PRODUCT TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

FIGURE 29&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 30&nbsp;&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY INDICATION, 2021&ndash;2029 ($MILLION)

FIGURE 31&nbsp;&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY END USER, 2021&ndash;2029 ($MILLION)

FIGURE 32&nbsp;&nbsp;&nbsp;&nbsp;NORTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY COUNTRIES, 2021&ndash;2029 ($MILLION)

FIGURE 33&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , 2021&ndash;2029 ($MILLION)

FIGURE 34&nbsp;&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY PRODUCT TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

FIGURE 35&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 36&nbsp;&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY INDICATION, 2021&ndash;2029 ($MILLION)

FIGURE 37&nbsp;&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY END USER, 2021&ndash;2029 ($MILLION)

FIGURE 38&nbsp;&nbsp;&nbsp;&nbsp;SOUTH AMERICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY COUNTRIES, 2021&ndash;2029 ($MILLION)

FIGURE 39&nbsp;&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , 2021&ndash;2029 ($MILLION)

FIGURE 40&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY PRODUCT TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

FIGURE 41&nbsp;&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 42&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY INDICATION, 2021&ndash;2029 ($MILLION)

FIGURE 43&nbsp;&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY END USER, 2021&ndash;2029 ($MILLION)

FIGURE 44&nbsp;&nbsp;&nbsp;EUROPE LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY COUNTRIES, 2021&ndash;2029 ($MILLION)

FIGURE 45&nbsp;&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , 2021&ndash;2029 ($MILLION)

FIGURE 46&nbsp;&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY PRODUCT TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

FIGURE 47&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 48&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY INDICATION, 2021&ndash;2029 ($MILLION)

FIGURE 49&nbsp;&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY END USER, 2021&ndash;2029 ($MILLION)

FIGURE 50&nbsp;&nbsp;&nbsp;&nbsp;ASIA PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY COUNTRIES, 2021&ndash;2029 ($MILLION)

FIGURE 51&nbsp;&nbsp;&nbsp;MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET VALUE , 2021&ndash;2029 ($MILLION)

FIGURE 52&nbsp;&nbsp;&nbsp;&nbsp;MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY PRODUCT TYPE OF DELIVERY, 2021&ndash;2029 ($MILLION)

FIGURE 53&nbsp;&nbsp;&nbsp;&nbsp;MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY TYPE OF PACKAGING, 2021&ndash;2029 ($MILLION)

FIGURE 54&nbsp;&nbsp;&nbsp;&nbsp;MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY INDICATION, 2021&ndash;2029 ($MILLION)

FIGURE 55&nbsp;&nbsp;&nbsp;&nbsp;MIDDLE EAST &amp; AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET SHARE (%), BY END USER, 2021&ndash;2029 ($MILLION)

FIGURE 56.&nbsp;&nbsp;&nbsp;BECTON, DICKINSON AND COMPANY: FINANCIALS

FIGURE 57.&nbsp;&nbsp;&nbsp;BURRARD PHARMACEUTICALS: FINANCIALS

FIGURE 58.&nbsp;&nbsp;&nbsp;CIRONDRUGS: FINANCIALS

FIGURE 59&nbsp;&nbsp;S. G. BIOPHARM PVT. LTD: FINANCIALS

FIGURE 60.&nbsp;&nbsp;&nbsp;B. BRAUN MELSUNGEN AG: FINANCIALS

FIGURE 61.&nbsp;&nbsp;&nbsp;JUBILANT HOLLISTERSTIER LLC: FINANCIALS

FIGURE 62.&nbsp;&nbsp;&nbsp; MYLAN N.V.: FINANCIALS

FIGURE 63.&nbsp;&nbsp;&nbsp;RECIPHARM AB.: FINANCIALS

FIGURE 64.&nbsp;&nbsp;&nbsp;CORDENPHARMA INTERNATIONAL.: FINANCIALS

FIGURE 65.&nbsp;&nbsp;&nbsp;SCHOTT AG.: FINANCIALS